Recent Updates
Recently added Catalysts
HYFT Positive Sentiment

MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows

Key Takeaway: MindWalk Holdings Corp. has entered a multi-year agreement with Teva Pharmaceuticals Australia to implement its ReefIQ™ technology. This collaboration aims to enhance antibody-discovery workflows using MindWalk's HYFT®-powered biological context layer and LensAI™ analytical capabilities. The AI will assist Teva Australia in making informed discovery decisions based on predictive analytics.

Market Sentiment Analysis

POSITIVE FACTORS

  • MindWalk secures a multi-year agreement with Teva Australia.
  • Deployment of ReefIQ™ enhances antibody-discovery workflows.
  • AI capabilities will support informed discovery decisions.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd (“Teva Australia”) to deploy ReefIQ™, MindWalk’s HYFT®-powered biological context layer with specified LensAI™ analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia will use the AI capabilities to support discovery decisions based on generated predictions and ac

Frequently Asked Questions

What is the agreement between MindWalk and Teva Australia?

MindWalk has signed a multi-year agreement to support antibody discovery workflows.

What technology will MindWalk deploy for Teva?

MindWalk will deploy its ReefIQ™ technology with LensAI™ capabilities.

How will the AI technology assist Teva?

The AI will support discovery decisions based on generated predictions.

What is the purpose of the collaboration?

The collaboration aims to enhance antibody-discovery workflows.

Last updated: Nov 4, 2026